Literature DB >> 19424062

Adynamic bone disease: clinical and therapeutic implications.

João M Frazão1, Patrícia Martins.   

Abstract

PURPOSE OF REVIEW: Adynamic bone disease has recently been associated with increased risk of vascular calcification. This review focuses on the emerging data in adynamic bone disease, its clinical consequences and therapeutic implications. RECENT
FINDINGS: There is a lack of good biochemical markers of parathyroid status, bone formation and reabsorption to allow a secure diagnosis of bone disease. Recent data have suggested a possible link between bone activity and vascular calcification. Cardiovascular calcification is an independent predictor of mortality. Adynamic bone is associated with a very low capacity of bone to incorporate calcium in the bone compartment and inability to handle an extra calcium load. A positive association between vascular calcifications and low bone turnover has been suggested. Calcium-containing phosphate binders, active vitamin D therapy and high calcium dialysate may enhance vascular calcifications in the presence of adynamic bone disease.
SUMMARY: There is recent evidence suggesting a negative impact of calcium load in the progression of vascular calcification in dialysis patients with chronic kidney disease stage 5 with adynamic bone disease. The current therapeutic approach to these patients should focus on reduction of calcium and vitamin D load to restore parathyroid activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424062     DOI: 10.1097/MNH.0b013e32832c4df0

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  14 in total

1.  Histomorphometric diagnostics of renal osteopathy in chronic dialysis patients at high risk of cardiovascular disease.

Authors:  K Žamboch; K Krejčí; J Škarda; M Tichý; I Überall; P Skýpalová; K Langová; D Stejskal; M Švesták; J Zahálková; V Ščudla; J Zadražil
Journal:  Int Urol Nephrol       Date:  2015-05-01       Impact factor: 2.370

2.  Serum osteocalcin levels are useful as a predictor of cardiovascular events in maintenance hemodialysis patients.

Authors:  Tetsuri Yamashita; Kazuhiro Okano; Yuki Tsuruta; Takashi Akiba; Kosaku Nitta
Journal:  Int Urol Nephrol       Date:  2012-03-24       Impact factor: 2.370

Review 3.  Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window.

Authors:  Uwe Querfeld; Robert H Mak
Journal:  Pediatr Nephrol       Date:  2010-06-22       Impact factor: 3.714

4.  Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis.

Authors:  Haimanot Wasse; Rong Huang; Qi Long; Salman Singapuri; Paolo Raggi; Vin Tangpricha
Journal:  Am J Clin Nutr       Date:  2012-01-11       Impact factor: 7.045

5.  Chronic kidney disease and bone metabolism.

Authors:  Junichiro James Kazama; Koji Matsuo; Yoshiko Iwasaki; Masafumi Fukagawa
Journal:  J Bone Miner Metab       Date:  2015-02-05       Impact factor: 2.626

6.  Treatment of Hyperparathyroidism (SHPT).

Authors:  Fabiana Rodrigues Hernandes; Patrícia Goldenstein; Melani Ribeiro Custódio
Journal:  J Bras Nefrol       Date:  2021-12-03

7.  Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients.

Authors:  Sunita Sardiwal; Clare Gardham; Adrian E Coleman; Paul E Stevens; Michael P Delaney; Edmund J Lamb
Journal:  Kidney Int       Date:  2012-03-28       Impact factor: 10.612

Review 8.  Chronic kidney disease and the skeleton.

Authors:  Paul D Miller
Journal:  Bone Res       Date:  2014-12-23       Impact factor: 13.567

9.  Differentially expressed miR-3680-5p is associated with parathyroid hormone regulation in peritoneal dialysis patients.

Authors:  Sohyun Jeong; Jung Mi Oh; Kook-Hwan Oh; In-Wha Kim
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

Review 10.  Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation.

Authors:  Jordi Bover; Mario Cozzolino
Journal:  Kidney Int Suppl (2011)       Date:  2011-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.